Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer

Background: The DESTINY-Breast03 clinical trial demonstrated that trastuzumab deruxtecan (T-DXd) outperformed trastuzumab emtansine (T-DM1) in progression-free survival (PFS) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (mBC). Considering the exc...

Full description

Bibliographic Details
Main Authors: Jiangping Yang, Jiaqi Han, Yalan Zhang, Muhelisa Muhetaer, Nianyong Chen, Xi Yan
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Pharmacology
Subjects:
cost-effectiveness
trastuzumab deruxtecan
trastuzumab emtansine
HER2-positive breast cancer
antibody-drug conjugates
target therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.924126/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.924126/full

Similar Items